Skandinaviska Enskilda Banken AB publ Has $15.22 Million Holdings in Hologic, Inc. (NASDAQ:HOLX)

Skandinaviska Enskilda Banken AB publ trimmed its position in Hologic, Inc. (NASDAQ:HOLX - Free Report) by 35.9% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 210,664 shares of the medical equipment provider's stock after selling 118,100 shares during the quarter. Skandinaviska Enskilda Banken AB publ owned approximately 0.09% of Hologic worth $15,223,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently modified their holdings of the company. General Partner Inc. bought a new position in Hologic in the 4th quarter valued at about $26,000. Groupama Asset Managment raised its holdings in Hologic by 9.9% in the 3rd quarter. Groupama Asset Managment now owns 33,177 shares of the medical equipment provider's stock valued at $27,000 after acquiring an additional 2,999 shares during the period. Venturi Wealth Management LLC raised its holdings in Hologic by 156.3% in the 4th quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider's stock valued at $31,000 after acquiring an additional 261 shares during the period. First Horizon Advisors Inc. raised its holdings in Hologic by 38.3% in the 3rd quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider's stock valued at $39,000 after acquiring an additional 134 shares during the period. Finally, EverSource Wealth Advisors LLC raised its holdings in Hologic by 79.8% in the 4th quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider's stock valued at $42,000 after acquiring an additional 260 shares during the period. 94.73% of the stock is owned by institutional investors.

Remove Ads

Hologic Price Performance

Shares of NASDAQ HOLX traded up $0.16 during trading hours on Tuesday, hitting $61.98. 3,766,525 shares of the stock were exchanged, compared to its average volume of 2,402,273. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.78 and a current ratio of 3.49. The company has a market cap of $13.91 billion, a PE ratio of 19.55, a price-to-earnings-growth ratio of 2.14 and a beta of 0.97. The company's fifty day simple moving average is $66.94 and its two-hundred day simple moving average is $74.51. Hologic, Inc. has a 1-year low of $60.33 and a 1-year high of $84.67.

Hologic (NASDAQ:HOLX - Get Free Report) last issued its earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share for the quarter, beating analysts' consensus estimates of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. On average, sell-side analysts predict that Hologic, Inc. will post 4.28 EPS for the current year.

Wall Street Analyst Weigh In

Several research firms have weighed in on HOLX. Evercore ISI lowered their price target on shares of Hologic from $76.00 to $73.00 and set an "in-line" rating on the stock in a report on Thursday, February 6th. Needham & Company LLC cut shares of Hologic from a "buy" rating to a "hold" rating and set a $90.00 price target on the stock. in a report on Monday, February 3rd. Wolfe Research began coverage on shares of Hologic in a report on Friday, December 13th. They issued a "peer perform" rating on the stock. William Blair reissued an "outperform" rating on shares of Hologic in a report on Thursday, February 6th. Finally, Argus cut shares of Hologic from a "buy" rating to a "hold" rating in a report on Monday, March 3rd. Eleven investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Hold" and an average price target of $84.62.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.